# q01 rev 3 - blind solver B (fresh blind-solver, packet solver-2), 2026-10-06

Raw return as received:

answer: Flat. When the U.S. Consulting Services sale closed in April 2026, Cencora's guidance called for flat fiscal 2026 adjusted operating income in "Other". Other is not a reportable segment, and it held the unit at that point. The comparison base was fiscal 2025 actual adjusted operating income of $352M, so the guidance implied about 0% growth (roughly $352M).

confidence: high

path:
1. **Which category held the unit.** D06 (Q4 FY2025 release, Nov 5, 2025), line 121, under "Reportable Segments (revised as of October 1, 2025)":
   - "The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services)…"
   - "Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex."
   - D01 line 81 and D03 line 86 repeat this: "These businesses include MWI Animal Health, Profarma, U.S. Consulting Services, and certain components of PharmaLex."
2. **When it closed.** D05 (Q3 FY2026 release, Aug 5, 2026):
   - Line 81: "U.S. Consulting Services (which was divested in April 2026)"
   - Line 95: "due to the April 2026 divestiture of U.S. Consulting Services"
3. **Fiscal 2026 adjusted operating income guidance for Other** (fiscal 2025 actual base is $352M in every table):
   - D06, Nov 5, 2025, line 138: "Other(1)|1% to 4% decline|$352M"
   - D01, Feb 4, 2026, line 114: "Other(2)|Flat|$352M". The reason is given at line 103: "improved results in Other as certain depreciable assets have been fully impaired as of December 31, 2025."
   - D03, May 6, 2026, line 123: "Other(2)|High-single digit growth|$352M". Line 112 presents this as a new change: "updated operating income expectations in Other as a result of MWI now being accounted for as 'held for sale'."
   - D05, Aug 5, 2026, line 118: "Other(2)|~10% growth|$352M"
4. **Which guidance was in force.** April 2026 falls after the Feb 4 release and before the May 6 release, so the Feb 4 guidance ("Flat") applied at closing. D03 line 17 supports that nothing changed in between: EPS guidance "has been raised from the previous range of $17.45 to $17.75." That is exactly the D01 range (D01 line 115), so there was no interim EPS update between Feb 4 and May 6.
5. **No calculation needed.** "Flat" against $352M means about 0% growth.

minimal_documents:
- **D01 + D05.** D01 gives the guidance and shows the unit in Other; D05 gives the April 2026 closing.
- **D03 as corroboration.** It shows the next guidance update came on May 6, after the closing, and that its "previous" EPS range matched D01.
- **Alternatives.** D06 can replace D01 or D03 for showing what Other contained, but not for the guidance figure. Nothing else in the packet supplies the Feb 2026 figure.

readings:
- **Most recent guidance before the closing (main reading):** Flat.
- **First guidance published after the closing (D03, May 6, 2026):** "High-single digit growth". This is weaker because it was issued after the closing and D03 doesn't mention the divestiture.
- **Wrong-date answers:** the original guidance (D06) said "1% to 4% decline"; the Aug 2026 guidance (D05) said "~10% growth". Neither was in force in April 2026.
- **Wrong category:** using U.S. Healthcare Solutions (the unit's former home) would give "14% to 16% growth" (D01 line 112). D06 explicitly removes U.S. Consulting Services from that segment starting fiscal 2026, so this doesn't fit "then included".

gaps:
- **No exact closing day.** The packet only says "April 2026". It has no deal announcement or 8-K between Feb 4 and May 6, 2026. An update outside the packet in that window can't be ruled out completely, though the D03 "previous range" points against one.
- **An interim update did happen later.** D05 line 17 cites a "previous range of $17.70 to $17.90", which isn't in the packet. It falls between May and August, after the closing, so it doesn't affect the answer.
- **Formatting lost.** The tables note that bold marks updated guidance, but bold doesn't survive in the text. The manifest lists every source as method "text" with no pages, so there was no original page to check. No Dnn.layout.txt files exist in this packet.
- **Coverage.** I read D01, D03, D05 and D06 through their guidance sections. Their reconciliation and financial tables, and all of D02 and D04 (FY2025 releases with no FY2026 guidance), were only keyword-searched.

contaminated: no

Relevant files:
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r3-v2-32031947d3dbdf85273e6007a056f3d7f3cc0e882e1d3c3f61c3417e759e0eeb\solver-2\text\D01.txt
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r3-v2-32031947d3dbdf85273e6007a056f3d7f3cc0e882e1d3c3f61c3417e759e0eeb\solver-2\text\D03.txt
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r3-v2-32031947d3dbdf85273e6007a056f3d7f3cc0e882e1d3c3f61c3417e759e0eeb\solver-2\text\D05.txt
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r3-v2-32031947d3dbdf85273e6007a056f3d7f3cc0e882e1d3c3f61c3417e759e0eeb\solver-2\text\D06.txt
